Peptides DB
Research-centric peptide and protocol reference hub
Study 14 of 23Vipivotide literaturePlant science : an international journal of experimental plant biology · Observational2026

Identification and functional verification of resistance genes against Lily bulb virus-1 (LbV-1) in Lilium: Insight from sRNA sequencing and transcriptomic profiling.

The study highlights the importance of screening commercial lily bulbs for latent viral infections and identifies potential genetic resistance mechanisms against LbV-1.

Read at Plant science : an international journal of experimental plant biologyAdd to compare

Where it sits

this study against the rest of the vipivotide corpus
3
Preclinical
14
Observational · this one
1
Open-label
3
Randomised
2
Reviews

Summary and findings

This study identified and characterized a novel mitovirus, Lily Bulb Virus-1 (LbV-1), in commercial lily bulb stocks. A survey of 50 lily bulbs revealed LbV-1 infection in a single cultivar, with an infection rate of up to 45% in progeny plants. Eight candidate genes were significantly upregulated in response to LbV-1 infection, with seven enhancing viral resistance when expressed in susceptible plants.

How much of this paper we could read: full text read (0.80). We had a clear abstract, so the summary below closely tracks the paper. What this means →
Infection rate of up to 45% in progeny plants.2026

Abstract

The authors’ words, as Plant science : an international journal of experimental plant biology supplied them

Lilium is an economically important genus widely cultivated for ornamental and commercial use. In this study, we report the identification and characterization of a novel mitovirus, designated Lily Bulb Virus-1 (LbV-1), detected in commercial lily bulb stocks. This virus represents a previously uncharacterized member of the mitochondrial RNA virus group associated with lily crops. A survey of 50 commercially cultivated lily bulbs, including Lilium longiflorum varieties, revealed LbV-1 infection in a single cultivar, indicating a low but detectable incidence under the tested conditions. Although infected plants exhibited no visible symptoms during in vitro cultivation, the presence of LbV-1 was confirmed through PCR amplification, small RNA (sRNA) sequencing, transmission electron microscopy (TEM), and mechanical inoculation assays. A total of 9122,220 unique sRNA reads were identified, with 21-22 nt virus-derived small RNAs mapping to the LbV-1 genome, supporting active host-virus interaction. Additionally, transcriptome-based analyses indicated efficient bulb-mediated transmission, with an infection rate of up to 45% in progeny plants. Comparative transcriptomic analysis of infected and healthy bulbs yielded over 30 million high-quality reads, resulting in the assembly of 3671,77 transcripts and 168,004 unigenes with an average length of 1445 bp. Differential expression analysis identified eight candidate genes (Li-PCP, Li-DUF, Li-UBD, Li-FRC, Li-CF, Li-APD, Li1-UN, and Li7-UN) that were significantly upregulated in response to LbV-1 infection and validated across three developmental stages using RT-qPCR. Functional analysis demonstrated that seven of these genes enhanced viral resistance when expressed in susceptible lily plants. These findings provide new insights into the molecular biology, transmission dynamics, and host defense responses associated with LbV-1. This study highlights the importance of systematic screening of commercial lily bulb stocks to prevent the unnoticed spread of latent viral infections and to safeguard sustainable lily production systems.

Elsewhere in the Vipivotide corpus

BTargeting Fibroblast Activation Protein with [177Lu]Lu-FAP-2286 in Patients with Advanced Solid Tumors in the Phase I LuMIERE Trial.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023 · n=27 · RP2D for 177Lu-FAP-2286 monotherapy determined to be 9.25 GBq.HumanBOverall Survival with [<sup>177</sup>Lu]Lu-PSMA-617 Versus [<sup>177</sup>Lu]Lu-PSMA I&T: A Propensity Score-Matched Real-World Analysis.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2023 · n=140 · Median OS: [177Lu]Lu-PSMA I&T: 14 mo; [177Lu]Lu-PSMA-617: 15 mo; hazard ratio, 1.18; 95% CI, 0.79-1.78; P = 0.42.HumanBReal-world outcomes of [<sup>177</sup>Lu]Lu-PSMA-I&T in [<sup>18</sup>F]FDG-positive metastatic castration-resistant prostate cancer: factors related to response and survival.European journal of nuclear medicine and molecular imaging · 2026 · n=25 · PSA30 response in 44% of patients.HumanBEffects of androgen receptor signaling inhibitors on absorbed doses in mCRPC patients undergoing [<sup>177</sup>Lu]Lu-PSMA-617 or [<sup>177</sup>Lu]Lu-PSMA-I&T therapy: dosimetry results.European journal of nuclear medicine and molecular imaging · 2026 · n=50 · 2.1 ± 4.0 Gy/GBq vs 1.5 ± 1.7 Gy/GBq for [177Lu]Lu-PSMA-617, p=0.24HumanALutetium-177-PSMA I&T (Lu-PSMA) with radiosensitising capecitabine in patients with metastatic castration-resistant prostate cancer (mCRPC): results of phase Ia study.European journal of nuclear medicine and molecular imaging · 2026 · n=12 · MTD established at 1000 mg/m².HumanBEvaluation of [<sup>225</sup>Ac]Ac-PSMA-617 vis-a-vis Rechallenge [<sup>177</sup>Lu]Lu-PSMA-617 PRLT Versus Cabazitaxel or Oral Metronomic Chemotherapy in mCRPC: An Observational Analysis of Outcome and Toxicity Profiles in a Real-World Clinical Scenario.The Prostate · 2026 · n=66 · PSA decline of >50% and disease control rate of 60% in [225Ac]Ac-PSMA-617 patients.Human